Principal Investigator |
ENARI Masato (2008-2009) National Cancer Center Research Institute and Research Center for Innovative Oncology, National Cancer Center Hospital East, 研究所生物学部, 室長 (90294058)
田矢 洋一 (2005-2007) National Cancer Center Research Institute and Research Center for Innovative Oncology, National Cancer Center Hospital East, (研究所)癌と細胞周期研究プロジェクト, プロジェクトリーダー (60133641)
|
|---|
| Budget Amount *help |
¥56,100,000 (Direct Cost: ¥56,100,000)
Fiscal Year 2009: ¥12,000,000 (Direct Cost: ¥12,000,000)
Fiscal Year 2008: ¥12,000,000 (Direct Cost: ¥12,000,000)
Fiscal Year 2007: ¥10,700,000 (Direct Cost: ¥10,700,000)
Fiscal Year 2006: ¥10,700,000 (Direct Cost: ¥10,700,000)
Fiscal Year 2005: ¥10,700,000 (Direct Cost: ¥10,700,000)
|
|---|
| Research Abstract |
We have previously identified clathrin heavy chain as a p53-binding protein. In this study, CHC is present in nuclei and promotes p53 transactivation through the enhancement of the interaction between p53 and p300, histone acetyltransferase. We also identified nuclear mitotic apparatus (NuMA)as a nuclear CHC-binding factor and showed that NuMA was a critical determinant for p53-transcriptional selectivity mediated by Cdk8. Moreover, the structural model of CHC-p53 interaction was constructed and an amino acid residue in CHC, which is important for p53 transactivation, was identified. Plasma membrane-associated p53 is involved in the regulation of CHC-dependent endocytosis and actin-mediated cell motility.
|
